Home LiteratureArticle Details
PMID: 6238433 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

The alternative pathway of complement.

Springer seminars in immunopathology ·Vol. 7 ·No. 2-3 ·1984-00-00 ·Pages 163-92

Pangburn MK, Müller-Eberhard HJ

Abstract

暂无摘要

MeSH Terms
Complement Activation Complement C3-C5 Convertases/metabolism Complement C3b/metabolism Complement C3b Inactivator Proteins/metabolism Complement Factor H Complement Factor I Complement Pathway, Alternative Endopeptidases/metabolism Erythrocytes/immunology Hemoglobinuria, Paroxysmal/immunology Humans Properdin/metabolism
Chemicals
CFH protein, human Complement C3b Inactivator Proteins Properdin Complement C3b Complement Factor H Endopeptidases Complement C3-C5 Convertases Complement Factor I
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Pangburn M K
Müller-Eberhard H J
References (148)
148 references, click to expand
  1. Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement.
    J Immunol. 1966 Nov;97(5):680-5 PMID: 5926456
  2. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.
    Science. 1954 Aug 20;120(3112):279-85 PMID: 13186838
  3. The immune adherence receptor: dissociation between the expression of erythrocyte and mononuclear cell C3b receptors.
    J Immunol. 1975 Nov;115(5):1312-5 PMID: 1100727
  4. Species specificity of recognition by the alternative pathway of complement.
    J Immunol. 1985 Feb;134(2):1101-4 PMID: 3155536
  5. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
    J Immunol. 1979 Jan;122(1):75-81 PMID: 762425
  6. Partial amino acid sequence of human factor D:homology with serine proteases.
    Proc Natl Acad Sci U S A. 1980 Feb;77(2):1116-9 PMID: 6987665
  7. Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenylaminocaproyldipalmitoylphosphatidylethaolamine.
    Immunology. 1983 Jan;48(1):129-40 PMID: 6848448
  8. Functional properties of membrane-associated complement receptor CR1.
    J Immunol. 1983 Apr;130(4):1876-80 PMID: 6220069
  9. Chemical characterization of cyanogen bromide fragments from the beta-chain of human complement factor C3.
    FEBS Lett. 1984 Apr 9;169(1):57-62 PMID: 6714418
  10. Properties of highly purified human properdin.
    J Immunol. 1968 Jan;100(1):142-58 PMID: 4169693
  11. Interaction between the third complement protein and cell surface macromolecules.
    Proc Natl Acad Sci U S A. 1977 Jul;74(7):2701-5 PMID: 268620
  12. The C3-activator system: an alternate pathway of complement activation.
    J Exp Med. 1971 Sep 1;134(3 Pt 2):90s-108s PMID: 4105810
  13. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.
    J Immunol. 1970 Jul;105(1):55-69 PMID: 4246566
  14. Studies on the sub-unit structure of human properdin.
    Immunochemistry. 1974 Jul;11(7):361-8 PMID: 4477550
  15. An equilibrium model of the metastable binding sites of alpha 2-macroglobulin and complement proteins C3 and C4.
    J Biol Chem. 1982 Oct 25;257(20):11864-7 PMID: 6181062
  16. Species-specific inhibition by glycophorins of complement activation via the alternative pathway.
    Mol Immunol. 1983 Nov;20(11):1233-6 PMID: 6656770
  17. The alternative pathway C3/C5 convertase: chemical basis of factor B activation.
    J Immunol. 1979 Aug;123(2):529-34 PMID: 458145
  18. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
    J Immunol. 1982 Dec;129(6):2603-7 PMID: 6923908
  19. T-lymphocytes escape membrane defect in paroxysmal nocturnal haemoglobinuria.
    Br J Haematol. 1983 Oct;55(2):263-71 PMID: 6604541
  20. C3 convertase of the human alternative pathway of complement: modulation of enzyme activity and stability by mouse monoclonal antibodies to Bb.
    Eur J Immunol. 1987 Feb;17(2):303-4 PMID: 3644748
  21. Characterization of the interaction of human C4b-binding protein with physiological ligands.
    J Biol Chem. 1984 Nov 25;259(22):13674-9 PMID: 6334079
  22. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties.
    Biochemistry. 1981 Jul 21;20(15):4458-67 PMID: 7284336
  23. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.
    J Exp Med. 1965 Aug 1;122:277-98 PMID: 14316946
  24. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683-7 PMID: 266208
  25. Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b.
    J Immunol. 1980 Feb;124(2):977-82 PMID: 7356723
  26. Mechanism of enhanced complement-dependent cytotoxicity of papain-treated lymphocytes: evidence for increased stability of classical pathway C3 convertase.
    J Immunol. 1982 Feb;128(2):866-70 PMID: 6915075
  27. Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences.
    J Immunol. 1980 Feb;124(2):602-6 PMID: 6766162
  28. The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways.
    Scand J Immunol. 1976;5(9):1049-55 PMID: 1006167
  29. Polymorphism of human erythrocyte C3b/C4b receptor.
    Proc Natl Acad Sci U S A. 1983 Mar;80(6):1698-702 PMID: 6572933
  30. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
    J Immunol. 1981 Jun;126(6):2370-2 PMID: 6785350
  31. Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement.
    J Immunol. 1983 Jun;130(6):2821-4 PMID: 6222117
  32. Control of the amplification convertase of complement by the plasma protein beta1H.
    Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72 PMID: 1067618
  33. Primate erythrocyte-immune complex-clearing mechanism.
    J Clin Invest. 1983 Feb;71(2):236-47 PMID: 6822663
  34. Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.
    J Immunol. 1979 Sep;123(3):1388-94 PMID: 38283
  35. Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.
    J Biol Chem. 1984 Oct 25;259(20):12685-90 PMID: 6567645
  36. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.
    J Clin Invest. 1973 May;52(5):1129-37 PMID: 4700488
  37. The separation of functionally distinct forms of the third component of human complement (C3).
    Biochem J. 1981 Mar 1;193(3):963-70 PMID: 6458280
  38. Structure of murine complement component C3. II. Nucleotide sequence of cloned complementary DNA coding for the alpha chain.
    J Biol Chem. 1984 Nov 25;259(22):13857-62 PMID: 6094532
  39. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Eur J Immunol. 1983 Jun;13(6):465-70 PMID: 6222909
  40. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.
    J Exp Med. 1983 Jun 1;157(6):1971-80 PMID: 6222136
  41. Molecular cloning and characterization of the gene coding for human complement protein factor B.
    Proc Natl Acad Sci U S A. 1983 Jul;80(14):4464-8 PMID: 6308626
  42. Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells.
    J Immunol. 1983 Mar;130(3):1336-40 PMID: 6218206
  43. Activation of the alternative complement pathway of guinea-gip by liposomes incorporated with trinitrophenylated phosphatidylethanolamine.
    Immunology. 1982 Jan;45(1):115-24 PMID: 6173312
  44. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    J Immunol. 1982 Jul;129(1):184-9 PMID: 6211481
  45. Mechanism of action of factor D of the alternative complement pathway.
    J Exp Med. 1978 Dec 1;148(6):1498-509 PMID: 82604
  46. Activation of complement via the alternative pathway.
    Fed Proc. 1983 Jan;42(1):139-43 PMID: 6217084
  47. Evidence for presence of an internal thiolester bond in third component of human complement.
    Proc Natl Acad Sci U S A. 1980 Oct;77(10):5764-8 PMID: 6934510
  48. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.
    J Exp Med. 1982 Jul 1;156(1):205-16 PMID: 6177820
  49. Amino acid sequence studies of human properdin--N-terminal sequence analysis and alignment of the fragments produced by limited proteolysis with trypsin and the peptides produced by cyanogen bromide treatment.
    Mol Immunol. 1981 Nov;18(11):949-59 PMID: 7341961
  50. Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.
    J Immunol. 1977 Feb;118(2):525-32 PMID: 839069
  51. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    J Exp Med. 1982 Dec 1;156(6):1739-54 PMID: 7175439
  52. C3 requirements for formation of alternative pathway C5 convertase.
    J Immunol. 1976 Aug;117(2):630-4 PMID: 950465
  53. Treatment of human complement components C4 and C3 with amines or chaotropic ions. Evidence of a functional and structural change that provides uncleaved C4 and C3 with properties of their soluble activated froms, C4b and C3b.
    Scand J Immunol. 1981;13(5):413-31 PMID: 6171865
  54. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Proc Natl Acad Sci U S A. 1983 Sep;80(17):5430-4 PMID: 6225118
  55. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement.
    J Biol Chem. 1982 Sep 10;257(17 ):9879-82 PMID: 6921201
  56. MHC Class III products: an electron microscopic study of the C3 convertases of human complement.
    J Exp Med. 1984 Jan 1;159(1):324-9 PMID: 6559206
  57. Pattern of degradation of human complement fragment, C3b.
    FEBS Lett. 1981 Sep 14;132(1):55-60 PMID: 6457754
  58. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.
    J Immunol. 1982 Mar;128(3):1278-83 PMID: 7035562
  59. The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.
    J Exp Med. 1966 Jan 1;123(1):33-54 PMID: 4159289
  60. Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway.
    Proc Natl Acad Sci U S A. 1978 Dec;75(12):6078-82 PMID: 282625
  61. Factor D of the alternative pathway of human complement. Purification, alignment and N-terminal amino acid sequences of the major cyanogen bromide fragments, and localization of the serine residue at the active site.
    Biochem J. 1980 Jun 1;187(3):863-74 PMID: 6821372
  62. On the lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by complement: dual role of C3b.
    Blut. 1982 Oct;45(4):249-59 PMID: 7126880
  63. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.
    Proc Natl Acad Sci U S A. 1978 Aug;75(8):3948-52 PMID: 279011
  64. The alternative pathway of complement activation.
    Adv Immunol. 1976;24:1-35 PMID: 798473
  65. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement.
    J Biol Chem. 1984 Apr 10;259(7):4582-8 PMID: 6707020
  66. The Budd-Chiari syndrome and paroxysmal nocturnal haemoglobinuria.
    Br J Haematol. 1981 May;48(1):1-6 PMID: 7018554
  67. Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody.
    J Exp Med. 1979 Sep 19;150(3):445-54 PMID: 479760
  68. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).
    Immunology. 1973 Feb;24(2):259-75 PMID: 4632688
  69. Modulation of the alternative complement pathways by beta 1 H globulin.
    J Exp Med. 1976 Nov 2;144(5):1147-63 PMID: 62817
  70. Competition for immune complexes by red cells in human blood.
    J Clin Lab Immunol. 1982 Jan;7(1):7-13 PMID: 7069779
  71. Properdin factor D: characterization of its active site and isolation of the precursor form.
    J Exp Med. 1974 Feb 1;139(2):355-66 PMID: 4855753
  72. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    J Immunol. 1984 Apr;132(4):1960-6 PMID: 6607952
  73. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971-5 PMID: 273923
  74. The structure and function of the third component of human complement--I. The nature and extent of conformational changes accompanying C3 activation.
    Mol Immunol. 1981 Apr;18(4):331-9 PMID: 7300834
  75. Cobra venom factor: improved method for purification and biochemical characterization.
    J Immunol Methods. 1984 Oct 12;73(1):203-20 PMID: 6491300
  76. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c.
    Proc Natl Acad Sci U S A. 1982 Aug;79(16):5047-51 PMID: 6214790
  77. The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.
    J Immunol. 1968 Apr;100(4):691-8 PMID: 5645214
  78. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71 PMID: 293688
  79. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte.
    J Exp Med. 1980 Jul 1;152(1):20-30 PMID: 6967510
  80. Structural characterization of factor I mediated cleavage of the third component of complement.
    Biochemistry. 1982 Nov 9;21(23):5745-9 PMID: 6217832
  81. Cobra venom factor: structural homology with the third component of human complement.
    J Immunol. 1984 Dec;133(6):3235-41 PMID: 6491285
  82. Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I.
    Biochemistry. 1983 Jan 4;22(1):178-85 PMID: 6219696
  83. Amino acid sequence of human factor D of the complement system. Similarity in sequence between factor D and proteases of non-plasma origin.
    FEBS Lett. 1984 Jan 30;166(2):347-51 PMID: 6363133
  84. Lysis of erythrocytes by complement in the absence of antibody.
    J Exp Med. 1970 Nov;132(5):898-915 PMID: 5470509
  85. Purification of the human complement control protein C3b inactivator.
    Biochem J. 1980 Oct 1;191(1):173-82 PMID: 6451220
  86. Mechanism of action of the C3b inactivator: requirement for a high molecular weight cofactor (C3b-C4bINA cofactor) and production of a new C3b derivative (C3b').
    Immunochemistry. 1977 Nov-Dec;14(11-12):749-56 PMID: 146022
  87. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Proc Natl Acad Sci U S A. 1978 May;75(5):2416-20 PMID: 276881
  88. Binding of C3b proceeds by a transesterification reaction at the thiolester site.
    Nature. 1982 Jul 1;298(5869):72-5 PMID: 6806664
  89. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.
    J Exp Med. 1980 Oct 1;152(4):1102-14 PMID: 6903192
  90. RELATION OF A beta(1)-GLYCOPROTEIN OF HUMAN SERUM TO THE COMPLEMENT SYSTEM.
    J Exp Med. 1960 Jan 31;111(2):217-34 PMID: 19867170
  91. The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b.
    J Exp Med. 1979 Aug 1;150(2):267-76 PMID: 458376
  92. Covalent binding and hemolytic activity of complement proteins.
    Proc Natl Acad Sci U S A. 1980 Dec;77(12):7194-8 PMID: 6938964
  93. Restriction of alternative complement pathway activation by sialosylglycolipids.
    Nature. 1982 Sep 16;299(5880):261-3 PMID: 7110347
  94. Binding reaction between the third human complement protein and small molecules.
    Biochemistry. 1981 Dec 22;20(26):7457-63 PMID: 7326238
  95. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    J Exp Med. 1975 Sep 1;142(3):760-72 PMID: 1165475
  96. Mapping of the properdin-binding site in the third component of complement.
    Biochem J. 1984 Jan 1;217(1):323-6 PMID: 6696726
  97. Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins.
    J Exp Med. 1978 Dec 1;148(6):1722-7 PMID: 722244
  98. The physiological breakdown of the third component of human complement.
    Mol Immunol. 1980 Jan;17(1):9-20 PMID: 7360115
  99. Localization of the conglutinin binding site on the third component of human complement.
    J Immunol. 1985 Feb;134(2):1105-9 PMID: 3965568
  100. Structural requirements of rabbit IgG F(ab')2 fragment for activation of the complement system through the alternative pathway--I. Disulfide bonds.
    Mol Immunol. 1981 Oct;18(10):925-34 PMID: 7335085
  101. Properdin is a trimer.
    Mol Immunol. 1982 Apr;19(4):631-5 PMID: 7087966
  102. Characterization of alkylamine-sensitive site in alpha 2-macroglobulin.
    Proc Natl Acad Sci U S A. 1979 Sep;76(9):4313-6 PMID: 92026
  103. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate.
    J Biol Chem. 1982 Jul 25;257(14):8292-9 PMID: 6919543
  104. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
    J Immunol. 1980 Jan;124(1):326-31 PMID: 7350230
  105. The role of antibody in the activation of the alternative complement pathway.
    Springer Semin Immunopathol. 1983;6(4):361-71 PMID: 6364431
  106. Isolation of rabbit C3, Factor B, and Factor H and comparison of their properties with those of the human analog.
    J Immunol. 1985 Feb;134(2):1094-100 PMID: 3155535
  107. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    J Exp Med. 1981 Sep 1;154(3):856-67 PMID: 6912277
  108. Complement activation by the properdin system: formation of a stoichiometric. C3 cleaving complex of properdin factor B with C36.
    Immunochemistry. 1977 Mar;14(3):201-5 PMID: 863465
  109. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    J Clin Invest. 1979 Aug;64(2):428-33 PMID: 457861
  110. A molecular concept of the properdin pathway.
    Proc Natl Acad Sci U S A. 1976 Feb;73(2):612-6 PMID: 54923
  111. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.
    Immunochemistry. 1969 May;6(3):405-19 PMID: 5786934
  112. A new function of the activated third component of complement: binding to C5, an essential step for C5 activation.
    Immunology. 1978 Jan;34(1):29-40 PMID: 624565
  113. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    J Exp Med. 1979 Nov 1;150(5):1202-15 PMID: 501288
  114. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    J Exp Med. 1976 Oct 1;144(4):1076-93 PMID: 978134
  115. Lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by acid-activated serum.
    Immunobiology. 1983 Mar;164(2):118-26 PMID: 6852860
  116. Molecular biology and chemistry of the alternative pathway of complement.
    Adv Immunol. 1980;29:1-53 PMID: 6158260
  117. The covalent-binding reaction of complement component C3.
    Biochem J. 1981 Jan 1;193(1):115-27 PMID: 7305916
  118. The binding of activated C3 to polysaccharides and immunoglobulins.
    J Immunol. 1978 Dec;121(6):2566-72 PMID: 722084
  119. Lack of binding of human C3, in its native state, to C3b receptors.
    J Immunol. 1981 Oct;127(4):1329-34 PMID: 7276560
  120. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.
    Clin Exp Immunol. 1975 Jul;21(1):109-14 PMID: 52423
  121. Initiation of C3 cleavage in the alternative complement pathway.
    J Immunol. 1975 Nov;115(5):1357-61 PMID: 809512
  122. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
    Biochem J. 1981 Dec 1;199(3):485-96 PMID: 6462133
  123. Extraction of complement inhibitory factors from the erythrocytes of non-human species.
    J Immunol. 1973 Sep;111(3):946-51 PMID: 4741303
  124. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.
    J Exp Med. 1977 Jul 1;146(1):257-70 PMID: 301546
  125. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
    Proc Natl Acad Sci U S A. 1981 Dec;78(12):7707-11 PMID: 6950410
  126. Genetic regulation of a structural polymorphism of human C3b receptor.
    J Clin Invest. 1983 Aug;72(2):685-93 PMID: 6223944
  127. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
    J Exp Med. 1975 Oct 1;142(4):856-63 PMID: 1185108
  128. Complement receptor is an inhibitor of the complement cascade.
    J Exp Med. 1981 May 1;153(5):1138-50 PMID: 6910481
  129. C3 proactivator convertase and its mode of action.
    J Exp Med. 1972 Apr 1;135(4):1003-8 PMID: 4111773
  130. Paroxysmal nocturnal haemoglobinuria in aplastic anaemia.
    Clin Haematol. 1978 Oct;7(3):541-53 PMID: 363327
  131. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Proc Natl Acad Sci U S A. 1983 Aug;80(16):5066-70 PMID: 6576376
  132. Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.
    Immunochemistry. 1969 May;6(3):391-403 PMID: 5786933
  133. C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex.
    J Biol Chem. 1983 Jun 25;258(12):7411-5 PMID: 6553050
  134. Activation of the complement system.
    Contemp Top Mol Immunol. 1973;2:155-83 PMID: 4129483
  135. The induction of macrophage spreading by factor B of the properdin system.
    J Exp Med. 1979 Feb 1;149(2):372-86 PMID: 570212
  136. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    J Exp Med. 1977 Jul 1;146(1):22-33 PMID: 559720
  137. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Proc Natl Acad Sci U S A. 1979 Dec;76(12):6596-600 PMID: 293746
  138. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.
    J Immunol. 1982 Nov;129(5):2051-60 PMID: 6214588
  139. Antibody-independent activation of the alternative complement pathway by measles virus-infected cells.
    Proc Natl Acad Sci U S A. 1980 Jan;77(1):559-62 PMID: 6928644
  140. Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation.
    Biochemistry. 1980 Sep 16;19(19):4471-8 PMID: 7407085
  141. Third component of human complement: structural requirements for its function.
    Biochemistry. 1980 Sep 16;19(19):4479-85 PMID: 7407086
  142. Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins.
    J Exp Med. 1979 Apr 1;149(4):870-82 PMID: 372483
  143. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.
    J Immunol. 1983 Oct;131(4):1930-5 PMID: 6225800
  144. Characterization of the initial C3 convertase of the alternative pathway of human complement.
    J Immunol. 1984 Mar;132(3):1430-4 PMID: 6559201
  145. C3 modified at the thiolester site: acquisition of reactivity with cellular C3b receptors.
    Biosci Rep. 1981 Nov;1(11):873-80 PMID: 6458338
  146. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    J Immunol. 1984 Mar;132(3):1425-9 PMID: 6229580
  147. Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator.
    J Exp Med. 1978 Oct 1;148(4):1044-51 PMID: 702059
  148. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    J Immunol. 1983 Aug;131(2):892-8 PMID: 6863934
Article Info
Journal
Springer seminars in immunopathology
Abbr.
Springer Semin Immunopathol
ISSN
0344-4325
DOI
10.1007/BF01893019
Published
1984-00-00
Pages
163-92
Language
English
Region
Germany
NLM ID
7910384
Subset
IM
Grants
NIAID NIH HHS · AI 17354 · United States
NCI NIH HHS · CA 27489 · United States
NHLBI NIH HHS · HL 16411 · United States
External Links
PubMed source DOI: 10.1007/BF01893019
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2